The results of the Phase 3, placebo-controlled SUCCEED trial, which evaluated the oral mTOR inhibitor ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy, have shown that the primary endpoint of progression-free survival has been met to maintain the benefit of prior chemotherapy, as reported at the American Society of Clinical Oncology's 2011 ...
Sign in with your MPR account
Keep me signed in Forgot your password?
REGISTER FOR FREE WITH A MPR ACCOUNT
Enter your MPR registration email address to receive a new password.